| 000 | 03766nam a22005177a 4500 | ||
|---|---|---|---|
| 008 | 190621s20192019 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a0923-7534 | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a31131397 | ||
| 245 | _aAvoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?. [Review] | ||
| 251 | _aAnnals of Oncology. 30(7):1044-1050, 2019 07 01. | ||
| 252 | _aAnn Oncol. 30(7):1044-1050, 2019 07 01. | ||
| 252 | _zAnn Oncol. 2019 Apr 09 | ||
| 253 | _aAnnals of oncology : official journal of the European Society for Medical Oncology | ||
| 260 | _c2019 | ||
| 260 | _fFY2020 | ||
| 265 | _saheadofprint | ||
| 265 | _sppublish | ||
| 266 | _d2019-06-21 | ||
| 268 | _aAnnals of Oncology. 2019 Apr 09 | ||
| 269 | _fFY2019 | ||
| 520 | _aCopyright (c) The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]. | ||
| 520 | _aPrediction of benefit from adjuvant chemotherapy following resection of early breast cancer and, as a result, proper selection of candidates remains an elusive goal since the relative magnitude of benefit is the same regardless of the presence of clinicopathologic factors. Multiple studies, including randomized trials, establish the role of certain gene expression signatures in node-negative disease since they predict the risk of breast cancer relapse being so low that adjuvant chemotherapy can be omitted. In contrast, more limited data are available in higher risk, node-positive breast cancer patients, making the exclusion of adjuvant chemotherapy potentially hazardous. 'Prospective-retrospective' studies and limited prospective data show that several signatures, namely Oncotype Dx, MammaPrint, Prosigna, EndoPredict and Breast Cancer Index, select with different levels of success node-positive patients at very low risk for distant recurrence despite not receiving chemotherapy, although the long-term follow-up is still awaited. Pending, however the publication of the results from ongoing randomized studies which enroll patients with node-positive disease, major caution is warranted. Improper use and misinterpretation of these transcriptomic profiles can lead to undertreatment and exposure of patients to unnecessary risks resulting in increased breast cancer mortality for patients with axillary node-positive disease. With this review we critically discuss the available data on gene expression signatures that are used in clinical practice and offer practical recommendations regarding the management of patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive breast cancer. | ||
| 546 | _aEnglish | ||
| 650 | _a*Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | ||
| 650 | _a*Breast Neoplasms/ge [Genetics] | ||
| 650 | _a*Breast Neoplasms/th [Therapy] | ||
| 650 | _a*Lymph Nodes/pa [Pathology] | ||
| 650 | _aBreast Neoplasms/pa [Pathology] | ||
| 650 | _aDecision Making | ||
| 650 | _aFemale | ||
| 650 | _aGene Expression Profiling/mt [Methods] | ||
| 650 | _aHumans | ||
| 650 | _aMastectomy/mt [Methods] | ||
| 650 | _aPrecision Medicine/mt [Methods] | ||
| 650 | _aPrognosis | ||
| 650 | _aRandomized Controlled Trials as Topic | ||
| 650 | _aTranscriptome | ||
| 651 | _aMedStar Health | ||
| 656 | _aAssociate Dean for Research Development | ||
| 657 | _aJournal Article | ||
| 700 | _aSwain, Sandra | ||
| 790 | _aBergh J, Foukakis T, Matikas A, Swain S | ||
| 856 |
_uhttps://dx.doi.org/10.1093/annonc/mdz126 _zhttps://dx.doi.org/10.1093/annonc/mdz126 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c4313 _d4313 |
||